ERBB2 and ductal breast carcinoma in situ: A previous DC1-polarized dendritic cell-based neoadjuvant vaccine trial to treat early breast cancer (HER-2pos ductal carcinoma in situ; DCIS) generated strong and durable Th1-polarized immunity against HER-2 [8, 9].